Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
Jie Hu#, Pai Peng#, Xiaoxia Cao#, Kang Wu, Quan-xin Long, Juan Chen, Kai Wang, Ni Tang and Ai-long Huang*
A new detected SARS-CoV-2 variant Omicron (B.1.1.529) had reported from more than 80 countries. In the past few weeks, a new wave of infection driven by Omicron is in progress. Omicron Spike (S) protein pseudotyped virus was used to determine the effect of S mutations on its capacity of infectivity and immune evasion. Our results showed the lower entry efficiency and less cleavage ability of Omicron than D614G variant. Pseudotype-based neutralizing assay was performed to analyze neutralizing antibodies elicited by previously infection or the RBD-based protein subunit vaccine ZF2001 against the Omicron variant. Sera sampled at around one month after symptom onset from 12 convalescents who were previously infected by SARS-CoV-2 original strain shows a more than 20-fold decrease of neutralizing activity against Omicron variant, when compared to D614G variant. Among 12 individuals vaccinated by RBD subunit vaccine, 58.3% (7/12) sera sampled at 15-60 days after 3rd-dose vaccination did not neutralize Omicron. Geometric mean titers (GMTs, 50% inhibitory dose [ID50]) of these sera against Omicron were 9.4-fold lower than against D614G. These results suggested a higher risk of Omicron breakthrough infections and reduced efficiency of the protective immunity elicited by existing vaccines. There are important implications about the modification and optimization of the current epidemic prevention and control including vaccine strategies and therapeutic antibodies against Omicron variant.
Doi: 10.1038/s41423-021-00836-z
Full text: https://www.nature.com/articles/s41423-021-00836-z
转载本文请联系原作者获取授权，同时请注明本文来自汪凯科学网博客。
链接地址：https://wap.sciencenet.cn/blog-446272-1320736.html?mobile=1
收藏
